Jignesh Dalal

Dr. Jignesh Dalal

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2019 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
TCthe United States Immunodeficiency Network Consortium
the United States Immunodeficiency Network Consortium
JYJennifer R. Yonkof
Jennifer R. Yonkof
AGAshish Gupta
Ashish Gupta
PFPingfu Fu
Pingfu Fu
EGElizabeth Garabedian
Elizabeth Garabedian
JDJignesh Dalal
Jignesh Dalal

Verified
Journal Article
Open access
PDF file
ARArchana Ramgopal
Archana Ramgopal
SSShiva Sridar
Shiva Sridar
JDJignesh Dalal
Jignesh Dalal
RKRamasubramanian Kalpatthi
Ramasubramanian Kalpatthi
Thrombotic microangiopathy (TMA) is a rare but serious complication of hematopoietic stem cell transplantation (HSCT). The purpose of our study is to estimate the incidence, prevalence, and analyze the risk factors and outcome of TMA in children receiving HSCT. Patients under the age of 21 who underwent HSCT at one of the 42 Pediatric Health Information System (PHIS) hospitals from 2000–2012 were analyzed, including demographics, hospitalizations, TMA, and other HSCT-related complications. From 2000 to 2012, a total of 12,369 unique pediatric patients who received HSCT were identified. Among these, 93 (0.8%) children were identified to have the diagnosis of TMA. TMA was significantly associated with allogeneic HSCT, peripheral blood stem cell trasnplants (PBSCT), cytomegalovirus (CMV), human herpes virus 6 (HHV6), fungal infection, graft-versus-host disease (GVHD), and veno-occlusive disease (VOD) (p = 0.01). Multivariate logistic regression analysis of mortality showed only HHV6 was an independent risk factor associated with increased mortality in patients with TMA (hazard ratio: 2.86 [1.01, 8.39], p = 0.05). The prevalence of TMA in our study is 0.8% with a mortality in our pediatric TMA cohort of 30%, which is in contrast to the higher mortality reported in previously published, small-case series. HHV6 emerged as not only a risk factor for TMA but also as associated with increased mortality in these patients.

1 December 2021 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
SVSmitha Hosahalli Vasanna
Smitha Hosahalli Vasanna
MPMaria A Pereda
Maria A Pereda
JDJignesh Dalal
Jignesh Dalal
Wiskott–Aldrich syndrome (WAS) is a rare X-linked recessive inborn error of immunity (IEI) first described in 1937. Classic WAS is characterized by the triad of thrombocytopenia with small platelets, recurrent infections due to combined immunodeficiency, and eczema. Hematopoietic stem cell transplantation (HSCT) was the only curative option available for five decades, with excellent outcomes reported for matched sibling donors (MSD) and matched unrelated donors (MUD). More recently, alternative donor transplants such as umbilical cord blood (UCB) and haploidentical transplant have emerged as viable options due to improvements in better graft selection, cell dosing, and effective allograft manipulation measures. Gene therapy is another potential curative option with promising results, yet currently is offered only as part of a clinical trial.

29 November 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
MPMaria A. Pereda
Maria A. Pereda
SVSmitha Hosahalli Vasanna
Smitha Hosahalli Vasanna
NDNeha J. Desai
Neha J. Desai
VDVictoria Deng
Victoria Deng
AOAmma Owusu-Ansah
Amma Owusu-Ansah
JDJignesh Dalal
Jignesh Dalal
Daratumumab, a CD38 monoclonal antibody that has been FDA-approved to treat multiple myeloma, has acquired popularity and is used off-label for both auto- and alloantibody mediated disorders, particularly in refractory/resistant circumstances. Much of the published data for its use in pediatric blood disorders has been in post-transplant autoimmune cytopenias. Here we describe three patients in whom daratumumab was used outside of post-transplant autoimmune cytopenias, highlighting further potential uses of this medication.

1 December 2020 in Current Oncology
Verified
Journal Article
Open access
JTJason Tay
Jason Tay
SBS. Beattie
S. Beattie
CBChristopher Bredeson
Christopher Bredeson
RBR. Brazauskas
R. Brazauskas
NHNa He
Na He
WSW. Saber
W. Saber
Background: Evidence about the impact of marital status before hematopoietic cell transplantation (hct) on outcomes after hct is conflicting. Methods: We identified patients 40 years of age and older within the Center for International Blood and Marrow Transplant Research registry who underwent hct between January 2008 and December 2015. Marital status before hct was declared as one of: married or living with a partner, single (never married), separated or divorced, and widowed. We performed a multivariable analysis to determine the association of marital status with outcomes after hct. Results: We identified 10,226 allogeneic and 5714 autologous hct cases with, respectively, a median follow-up of 37 months (range: 1–102 months) and 40 months (range: 1–106 months). No association between marital status and overall survival was observed in either the allogeneic (p = 0.58) or autologous (p = 0.17) setting. However, marital status was associated with grades 2–4 acute graft-versus-host disease (gvhd), p < 0.001, and chronic gvhd, p = 0.04. The risk of grades 2–4 acute gvhd was increased in separated compared with married patients [hazard ratio (hr): 1.13; 95% confidence interval (ci): 1.03 to 1.24], and single patients had a reduced risk of grades 2–4 acute gvhd (hr: 0.87; 95% ci: 0.77 to 0.98). The risk of chronic gvhd was lower in widowed compared with married patients (hr: 0.82; 95% ci: 0.67 to 0.99). Conclusions: Overall survival after hct is not influenced by marital status, but associations were evident between marital status and grades 2–4 acute and chronic gvhd. To better appreciate the effects of marital status and social support, future research should consider using validated scales to measure social support and patient and caregiver reports of caregiver commitment, and to assess health-related quality of life together with health care utilization.